Lapatinib, trastuzumab, and pertuzumab are all approved by the FDA to treat patients with early-stage and metastatic HER2-positive breast cancer as an adjuvant in combination with taxane therapy [11,13,14]. Here, ERBB2 is linked to breast cancer.